会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 71. 发明授权
    • Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase
    • 包含与修饰或非天然核碱基连接的配体的寡核苷酸
    • US07893224B2
    • 2011-02-22
    • US12533710
    • 2009-07-31
    • Muthiah ManoharanKallanthottathil G. RajeevJie Xia
    • Muthiah ManoharanKallanthottathil G. RajeevJie Xia
    • C07G3/00C07H21/04C12Q1/68
    • C07H21/00A61K31/7115C07F9/6561C07H21/02C12Q1/6883Y02A50/385Y02A50/387Y02A50/393Y02A50/395Y02A50/411Y02A50/463Y02A50/465Y02A50/467
    • One aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one ligand tethered to an altered or non-natural nucleobase. In certain embodiments, the non-natural nucleobase is difluorotolyl, nitropyrrolyl, or nitroimidazolyl. In certain embodiments, the ligand is a steroid or aromatic compound. In certain embodiments, only one of the two oligonucleotide strands comprising the double-stranded oligonucleotide contains a ligand tethered to an altered or non-natural nucleobase. In certain embodiments, both of the oligonucleotide strands comprising the double-stranded oligonucleotide independently contain a ligand tethered to an altered or non-natural nucleobase. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one ligand tethered to an altered or non-natural nucleobase. In certain embodiments, the non-natural nucleobase is difluorotolyl, nitropyrrolyl, or nitroimidazolyl. In certain embodiments, the ligand is a steroid or aromatic compound. In certain embodiments, the ribose sugar moiety that occurs naturally in nucleosides is replaced with a hexose sugar, polycyclic heteroalkyl ring, or cyclohexenyl group. In certain embodiments, at least one phosphate linkage in the oligonucleotide has been replaced with a phosphorothioate linkage.
    • 本发明的一个方面涉及包含至少一个与改变的或非天然核碱基连接的配体的双链寡核苷酸。 在某些实施方案中,非天然核碱基是二氟苯甲酰基,硝基吡咯基或硝基咪唑基。 在某些实施方案中,配体是类固醇或芳族化合物。 在某些实施方案中,包含双链寡核苷酸的两条寡核苷酸链中只有一条含有与改变的或非天然核碱基连接的配体。 在某些实施方案中,包含双链寡核苷酸的两条寡核苷酸链都独立地包含与改变的或非天然核碱基连接的配体。 在某些实施方案中,寡核苷酸链包含至少一个修饰的糖部分。 本发明的另一方面涉及包含至少一个与改变的或非天然核碱基连接的配体的单链寡核苷酸。 在某些实施方案中,非天然核碱基是二氟苯甲酰基,硝基吡咯基或硝基咪唑基。 在某些实施方案中,配体是类固醇或芳族化合物。 在某些实施方案中,在核苷中天然存在的核糖部分被己糖,多环杂烷基环或环己烯基取代。 在某些实施方案中,寡核苷酸中的至少一个磷酸键被硫代磷酸酯键取代。
    • 72. 发明授权
    • Oligonucleotides comprising a modified or non-natural nucleobase
    • 包含修饰或非天然核碱基的寡核苷酸
    • US07772387B2
    • 2010-08-10
    • US12495932
    • 2009-07-01
    • Muthiah ManoharanJie XiaKallanthottathil G. Rajeev
    • Muthiah ManoharanJie XiaKallanthottathil G. Rajeev
    • C07H21/02C07H21/04C12Q1/68
    • C07H21/00A61K31/7115C07F9/65515C07F9/65586C07F9/6561C07H21/02Y02A50/385Y02A50/387Y02A50/393Y02A50/395Y02A50/411Y02A50/463Y02A50/465Y02A50/467
    • One aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one non-natural nucleobase. In certain embodiments, the non-natural nucleobase is difluorotolyl, nitroindolyl, nitropyrrolyl, or nitroimidazolyl. In a preferred embodiment, the non-natural nucleobase is difluorotolyl. In certain embodiments, only one of the two oligonucleotide strands comprising the double-stranded oligonucleotide contains a non-natural nucleobase. In certain embodiments, both of the oligonucleotide strands comprising the double-stranded oligonucleotide independently contain a non-natural nucleobase. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one non-natural nucleobase. In a preferred embodiment, the non-natural nucleobase is difluorotolyl. In certain embodiments, the ribose sugar moiety that occurs naturally in nucleosides is replaced with a hexose sugar, polycyclic heteroalkyl ring, or cyclohexenyl group. In certain embodiments, at least one phosphate linkage in the oligonucleotide has been replaced with a phosphorothioate linkage.
    • 本发明的一个方面涉及包含至少一种非天然核碱基的双链寡核苷酸。 在某些实施方案中,非天然核碱基是二氟苯甲酰基,硝基吲哚基,硝基吡咯基或硝基咪唑基。 在优选的实施方案中,非天然核碱基是二氟苯甲酰基。 在某些实施方案中,包含双链寡核苷酸的两条寡核苷酸链中只有一条含有非天然核碱基。 在某些实施方案中,包含双链寡核苷酸的两条寡核苷酸链都独立地含有非天然核碱基。 在某些实施方案中,寡核苷酸链包含至少一个修饰的糖部分。 本发明的另一方面涉及包含至少一种非天然核碱基的单链寡核苷酸。 在优选的实施方案中,非天然核碱基是二氟苯甲酰基。 在某些实施方案中,在核苷中天然存在的核糖部分被己糖,多环杂烷基环或环己烯基取代。 在某些实施方案中,寡核苷酸中的至少一个磷酸键被硫代磷酸酯键取代。
    • 73. 发明授权
    • IRNA agents with biocleavable tethers
    • 具有生物可清除系绳的IRNA试剂
    • US07723509B2
    • 2010-05-25
    • US10985426
    • 2004-11-09
    • Muthiah ManoharanKallanthottathil G. Rajeev
    • Muthiah ManoharanKallanthottathil G. Rajeev
    • C07H21/04A61K31/70
    • C12N15/113C12N15/111C12N2310/14C12N2310/323C12N2310/3511C12N2320/51
    • The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose that further includes a tether having one or more linking groups, in which at least one of the linking groups is a cleavable linking group. The tether in turn can be connected to a selected moiety, e.g., a ligand, e.g., a targeting or delivery moiety, or a moiety which alters a physical property. The cleavable linking group is one which is sufficiently stable outside the cell such that it allows targeting of a therapeutically beneficial amount of an iRNA agent (e.g., a single stranded or double stranded iRNA agent), coupled by way of the cleavable linking group to a targeting agent—to targets cells, but which upon entry into a target cell is cleaved to release the iRNA agent from the targeting agent.
    • 本发明涉及iRNA试剂,其优选包括其中核糖部分已被核糖替代的单体,其进一步包括具有一个或多个连接基团的系链,其中至少一个连接基团是可切割的 连接组。 系链又可以连接到所选择的部分,例如配体,例如靶向或递送部分,或改变物理性质的部分。 可切割连接基团是在细胞外部足够稳定的连接基团,使得其允许靶向治疗有益量的iRNA试剂(例如,单链或双链iRNA试剂),其通过可切割连接基团连接至 靶向细胞靶向细胞,但是在进入靶细胞时被切割以从靶向剂释放iRNA试剂。
    • 74. 发明授权
    • Oligonucleotides comprising a modified or non-natural nucleobase
    • 包含修饰或非天然核碱基的寡核苷酸
    • US07579451B2
    • 2009-08-25
    • US11186915
    • 2005-07-21
    • Muthiah ManoharanJie XiaKallanthottathil G. Rajeev
    • Muthiah ManoharanJie XiaKallanthottathil G. Rajeev
    • C07H21/00C07H21/02C07H21/04C12Q1/68
    • C07H21/00A61K31/7115C07F9/65515C07F9/65586C07F9/6561C07H21/02Y02A50/385Y02A50/387Y02A50/393Y02A50/395Y02A50/411Y02A50/463Y02A50/465Y02A50/467
    • One aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one non-natural nucleobase. In certain embodiments, the non-natural nucleobase is difluorotolyl, nitroindolyl, nitropyrrolyl, or nitroimidazolyl. In a preferred embodiment, the non-natural nucleobase is difluorotolyl. In certain embodiments, only one of the two oligonucleotide strands comprising the double-stranded oligonucleotide contains a non-natural nucleobase. In certain embodiments, both of the oligonucleotide strands comprising the double-stranded oligonucleotide independently contain a non-natural nucleobase. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one non-natural nucleobase. In a preferred embodiment, the non-natural nucleobase is difluorotolyl. In certain embodiments, the ribose sugar moiety that occurs naturally in nucleosides is replaced with a hexose sugar, polycyclic heteroalkyl ring, or cyclohexenyl group. In certain embodiments, at least one phosphate linkage in the oligonucleotide has been replaced with a phosphorothioate linkage.
    • 本发明的一个方面涉及包含至少一种非天然核碱基的双链寡核苷酸。 在某些实施方案中,非天然核碱基是二氟苯甲酰基,硝基吲哚基,硝基吡咯基或硝基咪唑基。 在优选的实施方案中,非天然核碱基是二氟苯甲酰基。 在某些实施方案中,包含双链寡核苷酸的两条寡核苷酸链中只有一条含有非天然核碱基。 在某些实施方案中,包含双链寡核苷酸的两条寡核苷酸链都独立地含有非天然核碱基。 在某些实施方案中,寡核苷酸链包含至少一个修饰的糖部分。 本发明的另一方面涉及包含至少一种非天然核碱基的单链寡核苷酸。 在优选的实施方案中,非天然核碱基是二氟苯甲酰基。 在某些实施方案中,在核苷中天然存在的核糖部分被己糖,多环杂烷基环或环己烯基取代。 在某些实施方案中,寡核苷酸中的至少一个磷酸键被硫代磷酸酯键取代。
    • 75. 发明申请
    • Processes and Reagents for Desilylation of Oligonucleotides
    • 寡核苷酸脱甲酰化的方法和试剂
    • US20090005549A1
    • 2009-01-01
    • US12050633
    • 2008-03-18
    • Muthiah ManoharanMichael E. JungKallanthottathil G. RajeevRajendra K. PandeyGang Wang
    • Muthiah ManoharanMichael E. JungKallanthottathil G. RajeevRajendra K. PandeyGang Wang
    • C07H19/00
    • C07H21/00C07H21/04Y02P20/55
    • The present invention relates to processes and reagents for oligonucleotide synthesis and purification. One aspect of the present invention relates to compounds useful for activating phosphoramidites in oligonucleotide synthesis. Another aspect of the present invention relates to a method of preparing oligonucleotides via the phosphoramidite method using an activator of the invention. Another aspect of the present invention relates to sulfur-transfer agents. In a preferred embodiment, the sulfur-transfer agent is a 3-amino-1,2,4-dithiazolidine-5-one. Another aspect of the present invention relates to a method of preparing a phosphorothioate by treating a phosphite with a sulfur-transfer reagent of the invention. In a preferred embodiment, the sulfur-transfer agent is a 3-amino-1,2,4-dithiazolidine-5-one. Another aspect of the present invention relates to compounds that scavenge acrylonitrile produced during the deprotection of phosphate groups bearing ethylnitrile protecting groups. In a preferred embodiment, the acrylonitrile scavenger is a polymer-bound thiol. Another aspect of the present invention relates to agents used to oxidize a phosphite to a phosphate. In a preferred embodiment, the oxidizing agent is sodium chlorite, chloroamine, or pyridine-N-oxide. Another aspect of the present invention relates to methods of purifying an oligonucleotide by annealing a first single-stranded oligonucleotide and second single-stranded oligonucleotide to form a double-stranded oligonucleotide; and subjecting the double-stranded oligonucleotide to chromatographic purification. In a preferred embodiment, the chromatographic purification is high-performance liquid chromatography.
    • 本发明涉及寡核苷酸合成和纯化的方法和试剂。 本发明的一个方面涉及可用于在寡核苷酸合成中活化亚磷酰胺的化合物。 本发明的另一方面涉及使用本发明的活化剂通过亚磷酰胺方法制备寡核苷酸的方法。 本发明的另一方面涉及硫转移剂。 在优选的实施方案中,硫转移剂是3-氨基-1,2,4-二噻唑烷-5-酮。 本发明的另一方面涉及通过用本发明的硫转移试剂处理亚磷酸酯制备硫代磷酸酯的方法。 在优选的实施方案中,硫转移剂是3-氨基-1,2,4-二噻唑烷-5-酮。 本发明的另一方面涉及清除在带有乙腈基保护基团的磷酸酯基团去保护过程中产生的丙烯腈的化合物。 在优选的实施方案中,丙烯腈清除剂是聚合物结合的硫醇。 本发明的另一方面涉及用于将亚磷酸盐氧化成磷酸盐的试剂。 在优选的实施方案中,氧化剂是亚氯酸钠,氯胺或吡啶-N-氧化物。 本发明的另一方面涉及通过退火第一单链寡核苷酸和第二单链寡核苷酸来纯化寡核苷酸以形成双链寡核苷酸的方法; 并对双链寡核苷酸进行色谱纯化。 在优选的实施方案中,色谱纯化是高效液相色谱法。